Comparison Between Anterior Segment Optical Coherence Tomography and Ultrasound Bio Microscopy Parameters in Glaucoma Assessment

November 12, 2024 updated by: Marwa Adel Omar, Sohag University
Study aiming to compare between anterior segment Optical Coherence Tomography and Ultrasound BioMicroscopy In Glaucoma aSSESMENT

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Glaucoma is comprised of a group of optic neuropathies that share certain biological and clinical characteristics including progressive loss of the RGCs that causes specific, irreversible changes to the optic disc and visual field Visualization of the anterior chamber (AC) angle is a critical step in the diagnosis of glaucoma, especially angle-closure variants. .

UBM has been used in imaging and quantitative evaluation of anterior ocular segments since the 1990s. It allows in vivo observation of the anatomy and pathology of the anterior segments, from the conjunctiva and cornea to the iris and basal vitreous body, which provides significant information on glaucoma, cysts, neoplasms, trauma and foreign bodies. UBM also provides biometric information of anterior segment structures, such as anterior chamber (AC) depth, anterior chamber angle (ACA), and iris thickness. UBM provides more detailed information compared to slit-lamp, gonioscopy or B-scan examinations for diagnosis and follow-up of PAC eyes.In some cases UBM elucidates the mechanism of elevated intraocular pressure by showing the relationship between the peripheral iris and the trabecular meshwork. It can be used to study the causes of secondary glaucoma, for example, the pigment dispersion syndrome, lens-induced glaucoma, ciliary block, cysts, and solid tumors of the anterior segment. It can also assess the effects of various interventions such as laser iridotomy, trabeculectomy, and non-penetrating drainage surgery. Precise quantitative evaluation of the anterior chamber angle structures can help in diagnosis and management of various pathologies related to glaucoma . Optical coherence tomography (OCT) is a widely used non-invasive fundus imaging technique. Since the first application of OCT in the cornea in 2002], anterior segment-optical coherence tomography (AS-OCT) has developed rapidly. There are two major OCT platforms on the market: time domain-optical coherence tomography (TD-OCT) and spectral (or Fourier) domain-optical coherence tomography (SD/FD-OCT) . With a higher imaging resolution than UBM, AS-OCT makes it easier for the operator and software to identify ACA structures. such as: the scleral spur (SS), iris surface, Schwalbe's line, even trabecular meshwork (TM), and Schlemm's canal. This provides more precise analysis of the angle opening distance (AOD) from the SS, ACA, trabecular iris angle (TIA), and trabecular iris space area (TISA)

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt
        • Marwa Adel,

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

comparison between anterior segment optical coherence tomography and ultrasound biomicroscopy parameters in glaucoma assesment

Description

Inclusion Criteria:

  • Patients with open and angle closure glaucoma. Male and female patients were included. Patient age: more than18 years old

Exclusion Criteria:

Previous glaucoma surgery. Previous cataract surgery. Media opacity. Associated ocular or intra ocular inflammation. Associated corneal pathology.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ASOCT and UBM parameters Comparison
comparison between ASOCT and UBM parameters in glaucoma ASSESMENT
Device: ASOCT&UBM
glaucoma assesment by ASOCT &UBM
Drug: Glaucoma therapy
ASOCT and UBM parameters Comparison
Drug: Glaucoma therapy
Comparison
Other Names:
  • ASOCT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
comparison between Anterior Segment Optical Coherence Tomography And ltrasound Biomicroscopy Parameters In Glaucoma Assesment
Time Frame: 1 year

. UBM provides biometric information of anterior segment structures, such as anterior chamber (AC) depth, anterior chamber angle (ACA), and iris thickness. UBM provides more detailed information compared to slit-lamp, gonioscopy or B-scan examinations for diagnosis and follow-up of PAC eyes. It can be used to study the causes of secondary glaucoma. Precise quantitative evaluation of the anterior chamber angle structures can help in diagnosis and management of various pathologies related to glaucoma .

anterior segment-optical coherence tomography (AS-OCT) has developed rapidly. With a higher imaging resolution than UBM, AS-OCT makes it easier for the operator and software to identify ACA structures. such as: the scleral spur (SS), iris surface, Schwalbe's line, even trabecular meshwork , and Schlemm's canal. This provides more precise analysis of the angle opening distance from the SS, ACA, trabecular iris angle , and trabecular iris space area
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Study Director: Osama Ali, professor, Sohag University
  • Study Director: Islam Saad, Assistant, Sohag University
  • Study Chair: Mohamed Ezz, lecturer, Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2023

Primary Completion (Actual)

December 1, 2023

Study Completion (Estimated)

January 1, 2025

Study Registration Dates

First Submitted

January 31, 2023

First Submitted That Met QC Criteria

February 14, 2023

First Posted (Actual)

February 15, 2023

Study Record Updates

Last Update Posted (Actual)

November 15, 2024

Last Update Submitted That Met QC Criteria

November 12, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MAOmar

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma Eye

Clinical Trials on ASOCT&UBM

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe